BACKGROUND: The AutonoMe® implantation system with a preloaded, monofocal, aspherical, hydrophobic Clareon® intraocular lens (IOL) has recently become available. The aim of this analysis was the most comprehensive review of intraoperative and postoperative outcomes to date. METHODS: Prospective evaluation of intraoperative features in all eyes scheduled to have cataract surgery with Clareon® IOL implantation using the AutonoMe® implantation system between December 2017 and September 2018 with follow-up at 4-6 weeks. Inclusion of all patients, regardless of comorbidities and accompanying ocular surgery. RESULTS: A total of 391 eyes were evaluated for the intraoperative analysis and 144 eyes were evaluated for postoperative follow-up. There was one IOL-associated intraoperative complication in which the posterior haptic was not correctly loaded and should not have been implanted. The best corrected distance visual acuity (BCDVA) increased from a mean of 0.33 logMAR (SD 0.21) preoperatively to 0.09 logMAR (SD 0.21) postoperatively, independent of ocular comorbidities. The BCDVA in patients without ocular comorbidities increased from 0.27 logMAR (SD 0.13) preoperatively to 0.03 logMAR (SD 0.05) postoperatively. Using the SRK®/T formula 87.5% of all eyes had a refractive error of ≤0.5 D and 98.0% had a refractive error of ≤1 D 4-6 weeks after surgery. CONCLUSION: This study showed that using the recommended safety guidelines, the AutonoMe® system enables safe implantation of the IOL. The Clareon® IOL showed good postoperative visual outcomes and refraction results using the SRK®/T formula.
BACKGROUND: The AutonoMe® implantation system with a preloaded, monofocal, aspherical, hydrophobic Clareon® intraocular lens (IOL) has recently become available. The aim of this analysis was the most comprehensive review of intraoperative and postoperative outcomes to date. METHODS: Prospective evaluation of intraoperative features in all eyes scheduled to have cataract surgery with Clareon® IOL implantation using the AutonoMe® implantation system between December 2017 and September 2018 with follow-up at 4-6 weeks. Inclusion of all patients, regardless of comorbidities and accompanying ocular surgery. RESULTS: A total of 391 eyes were evaluated for the intraoperative analysis and 144 eyes were evaluated for postoperative follow-up. There was one IOL-associated intraoperative complication in which the posterior haptic was not correctly loaded and should not have been implanted. The best corrected distance visual acuity (BCDVA) increased from a mean of 0.33 logMAR (SD 0.21) preoperatively to 0.09 logMAR (SD 0.21) postoperatively, independent of ocular comorbidities. The BCDVA in patients without ocular comorbidities increased from 0.27 logMAR (SD 0.13) preoperatively to 0.03 logMAR (SD 0.05) postoperatively. Using the SRK®/T formula 87.5% of all eyes had a refractive error of ≤0.5 D and 98.0% had a refractive error of ≤1 D 4-6 weeks after surgery. CONCLUSION: This study showed that using the recommended safety guidelines, the AutonoMe® system enables safe implantation of the IOL. The Clareon® IOL showed good postoperative visual outcomes and refraction results using the SRK®/T formula.